FindTrial
Sign In

Comparing two doses of dexmedetomedine against lignocaine in decreasing the stress response to laryngoscopy and intubation

Comparative study between lignocaine and two different doses of dexmedetomidine on the attenuation of hemodynamic stress response in patients posted for elective oncosurgeries

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026647
Enrollment
210
Registered
2020-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D10-D36- Benign neoplasms, except benign neuroendocrine tumors Health Condition 2: D3A-D3A- Benign neuroendocrine tumors Health Condition 3: D00-D09- In situ neoplasms Health Condition 4: C40-C41- Malignant neoplasms of bone and articular cartilage Health Condition 5: C50-C50- Malignant neoplasms of breast Health Condition 6: C15-C26- Malignant neoplasms of digestive organs Health Condition 7: C69-C72- Malignant neoplasms of eye, brain and other parts of central nervous syste

Interventions

Intervention1: Dexmedetomidine 0.5 mcg/kg: Dose: Dexmedetomdine 0.5 mcg/kg diluted in 100 ml Normal saline, Duration: Given over 10 mins as infusion prior to induction Frequency: Bolus infusion( Once

Sponsors

Kidwai memorial insitute of Oncology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients consenting for study American society of anesthesiologists (ASA) status 1 and 2 Patients undergoing elective oncosurgeries

Exclusion criteria

Exclusion criteria: Patient refusal History of allergy to study drug Patients on Calcium channel blockers, beta blockers, ACE inhibitors Anticipated difficult airway More than two attempts at intubation History of Cerebrovascular accident, Ischemic Heart disease, Chronic Obstructive lung disease, Chronic Hypertension Impaired Renal function tests Impaired Liver function tests

Design outcomes

Primary

MeasureTime frame
No increase in Heart rate, Systolic blood pressure, Diastolic blood pressure, Mean arterial pressure with the intervention drug as compared to the baselineTimepoint: Baseline values Before induction before intubation 1 min after intubation 3 mins after intubation 5 mins after intubation 10 mins after intubation—

Secondary

MeasureTime frame
Development of Hypotension and Bradycardia with Study drugTimepoint: Baseline before study drug administration Before induction Before intubation 1 min after induction 3 mins after induction 5 mins after induction 10 mins after induction—

Countries

India

Contacts

Public ContactNevin Philip Mancha

Kidwai Memorial Institute of Oncology

vbchethana@gmail.com9845259264

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026